<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102517</url>
  </required_header>
  <id_info>
    <org_study_id>2007039</org_study_id>
    <nct_id>NCT01102517</nct_id>
  </id_info>
  <brief_title>A Trial on Video-assisted Thoracoscopic Surgery and Axillary Thoracotomy for Resection of Early-stage Non-small Cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the effects of VATS lobectomy for early-stage
      non-small cell lung cancer.

      The aims of this study are:

        1. To evaluate the early clinical benefits of VATS lobectomy when compared with the
           axillary thoracotomy.

        2. To evaluate the late effects of VATS lobectomy on survival and quality of life when
           compared with axillary thoracotomy.

        3. To establish the normative pattern of VATS lobectomy for early-stage non-small cell lung
           cancer.

        4. To explore the indication of VATS lobectomy for the lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival and overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>the first year after the surgery</time_frame>
    <description>Lung Cancer Symptom Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pulmonary function</measure>
    <time_frame>the first three months after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Karnofsky performance status</measure>
    <time_frame>the first year after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Chest Pain</measure>
    <time_frame>the first year after the surgery</time_frame>
    <description>visual analogue scale and Wong-Baker FACES Pain Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperation data</measure>
    <time_frame>perioperation</time_frame>
    <description>operation time, intraoperative blood loss, chest tube drainage amount, duration of the chest tube placement, and duratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines response</measure>
    <time_frame>the first 48 hours after the surgery</time_frame>
    <description>IL-2,IL-4,IL-6,IL-10,TNF,IFN-r</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>VATS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>video-assisted thoracoscopic surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>axillary thoracotomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>video-assisted thoracoscopic surgery</intervention_name>
    <description>video-assisted thoracoscopic surgery</description>
    <arm_group_label>VATS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>axillary thoracotomy</intervention_name>
    <description>axillary thoracotomy lobectomy</description>
    <arm_group_label>axillary thoracotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Early stage NSCLC and no metastasis of hilum of lung and mediastinum lymph nodes
             (short diameter ≤ 1 cm) on computed tomography (CT) scan;

          -  No medical contraindications to lung resection

          -  Age ≤ 75 years old and ≥18 years old;

          -  Sign the informed consent form.

        Exclusion Criteria:

          -  Evidence of invasion into neighboring organs;

          -  Extensive pleura adhesion;

          -  Central lesion;

          -  Not suitable for single-lung ventilation;

          -  Had history of thoracotomy and radiation for thoracic region ;

          -  Pregnancy or lactation female patients;

          -  Cannot sign the informed consent form because of psychological, family and society
             factors;

          -  Had history of other malignant tumors within 5 years except for non-melanoma cutaneous
             cancer, uterine cervix cancer in situ and curative early-stage carcinoma of prostate;

          -  Participants can not accept operation for other uncontrolled factors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Long, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.com/</url>
  </link>
  <reference>
    <citation>1.Bethencourt DM, Holmes EC. Muscle-sparing posterolateral thoracotomy. Ann Thorac Surg. 1988;45(3):337-339. 2.Ginsberg RJ. Alternative (muscle-sparing) incisions in thoracic surgery. Ann Thorac Surg. 1993;56(3):752-754. 3.Weissberg D, Kaufman M. Technical aids in surgery. Two muscle-sparing thoracotomies--techniques and indications. S Afr J Surg. 1990;28(1):17-19. 4.Akçali Y, Demir H, Tezcan B. The effect of standard posterolateral versus muscle-sparing thoracotomy on multiple parameters. Ann Thorac Surg. 2003;76(4):1050-1054. 5.Hazelrigg SR, Landreneau RJ, Boley TM, et al. The effect of muscle-sparing versus standard posterolateral thoracotomy on pulmonary function, muscle strength, and postoperative pain. J Thorac Cardiovasc Surg. 1991;101(3):394-400. 6.Kutlu CA, Akin H, Olcmen A, et al. Shoulder-girdle strength after standard and lateral muscle-sparing thoracotomy. Thorac Cardiovasc Surg. 2001;49(2):112-114. 7.Khan IH, McManus KG, McCraith A, et al. Muscle sparing thoracotomy: a biomechanical analysis confirms preservation of muscle strength but no improvement in wound discomfort. Eur J Cardiothorac Surg. 2000;18(6):656-661. 8.Baeza OR, Foster ED. Vertical axillary thoracotomy: a functional and cosmetically appealing incision. Ann Thorac Surg. 1976;22(3):287-288.</citation>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hao Long</investigator_full_name>
    <investigator_title>Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Clinical</keyword>
  <keyword>Early-stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

